Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United Kingdom

Clinical and Vaccine Immunology

Volumn 21, Issue 8, 2014, Pages 1164-1168

  Ramasamy, Maheshi N ^a   Clutterbuck, Elizabeth A ^a   Haworth, Kathryn ^a   Bowman, Jaclyn ^a   Omar, Omar ^a   Thompson, Amber J ^a   Blanchard Rohner, Geraldine ^b   Yu, Ly Mee ^a   Snape, Matthew D ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Department of Pediatrics   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACWYVAX; MENINGOCOCCAL QUADRIVALENT CONJUGATE VACCINE; MENINGOCOCCAL QUADRIVALENT POLYSACCHARIDE VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; MENINGOCOCCAL GROUP A POLYSACCHARIDE; MENINGOCOCCAL GROUP C POLYSACCHARIDE; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE; VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VACCINATION; VACCINATION REACTION; CLINICAL TRIAL; IMMUNOLOGY; MENINGITIS, MENINGOCOCCAL; MIDDLE AGED; UNITED KINGDOM; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; FEMALE; GREAT BRITAIN; HUMANS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84906658385     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00099-14     Document Type: Article

References (20)

1. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. 2008. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299: 173-184. http://dx.doi.org/10.1001/ jama.2007.29-c.
2. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. 2009. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J. 28:86-91. http://dx.doi.org/10.1097/INF. 0b013e31818a0237.
3. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
4. Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. 2010. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int. J. Infect. Dis. 14:e868-e875. http://dx.doi.org/10.1016/j.ijid.2010.03.017.
5. Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ. 2009. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood 114:4998-5002. http://dx.doi.org/10.1182/blood-2009-03-211052.
6. Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. 2010. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 28:4763-4770. http://dx.doi.org/10.1016/j.vaccine.2010.04.103.
7. Madore DV, Johnson-Kraines CL, Rothstein EP, Smith DH. 1999. Kinetics of antibody response to Haemophilus influenzae type b vaccines. Curr. Med. Res. Opin. 15:105-112. http://dx.doi.org/10.1185/03007999909113370. (Pubitemid 29306741)
8. Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, Borkowski A, Yu LM, Moxon ER, Pollard AJ. 2006. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin. Infect. Dis. 43:1387-1394. http://dx.doi.org/10.1086/508776. (Pubitemid 44845637)
9. Arjunaraja S, Massari P, Wetzler LM, Lees A, Colino J, Snapper CM. 2012. The nature of an in vivo anti-capsular polysaccharide response is markedly influenced by the composition and/or architecture of the bacterial subcapsular domain. J. Immunol. 188:569-577. http://dx.doi.org/10.4049/jimmunol.1101446.
10. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Branche WC, Harkins C. 1970. Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J. Infect. Dis. 121:372-377. http://dx.doi.org/10.1093/infdis/121.4.372.
11. Guerin PJ, Næss LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, Nabasumba C, Borrow R, Frøholm LO, Ghabri S, Batwala V, Twesigye R, Aaberge IS, Røttingen J-A, Piola P, Caugant DA. 2008. Immunogenicity of fractional doses of tetravalent A/C/Y/W135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Negl. Trop. Dis. 2:e342. http://dx.doi.org/10.1371/journal.pntd.0000342.
12. Trotter CL, Findlow H, Borrow R. 2012. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009. Clin. Vaccine Immunol. 19:219-222. http://dx.doi.org/10.1128/CVI.05515-11.
13. Danilova E, Shiryayev A, Kristoffersen EK, Sjursen H. 2005. Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus. Vaccine 23:4980-4983. http://dx.doi.org/10.1016/j.vaccine.2005.05.028. (Pubitemid 41267026)
14. Nicolay U, Girgsdies OE, Banzhoff A, Hundt E, Jilg W. 1999. Diphtheria booster vaccination: one or two injections? Vaccine 17:2223-2228. http://dx.doi.org/10.1016/S0264-410X(99)00013-4. (Pubitemid 29225673)
15. Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. 2009. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin. Vaccine Immunol. 16:1810-1815. http://dx.doi.org/10.1128/CVI. 00207-09.
16. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. 2009. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27:161-168. http://dx.doi.org/10.1016/j. vaccine.2008.08.075.
17. Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, Bianco V, Baine Y, Miller JM. 2011. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum. Vaccin. 7:239-247. http://dx.doi.org/10.4161/hv.7.2.14068.
18. Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, Dimaano E, Bianco V, Baine Y, Miller J. 2012. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum. Vaccin. Immunother. 8:873-880. http://dx.doi.org/10.4161/hv.20211.
19. Christensen H, May M, Bowen L, Hickman M, Trotter CL. 2010. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10:853-861. http://dx.doi.org/10.1016/S1473-3099(10)70251-6.
20. Weill J-C, Weller S, Reynaud C-A. 2009. Human marginal zone B cells. Annu. Rev. Immunol. 27:267-285. http://dx.doi.org/10.1146/annurev.immunol. 021908.132607.